Nav: Home

Study suggests additional benefits to HIV-prevention therapy

October 05, 2016

TORONTO--The anti-HIV drug Truvada has been shown to be very effective at preventing new infections when taken by people at high risk who strictly adhere to the drug therapy regime.

A new study suggests just how cost-effective this intervention -- known as pre-exposure prophylaxis, or PrEP -- could be in Toronto, and says there maybe additional benefits to a PrEP program if it brings high-risk individuals into contact with the health-care system and engages them in care.

Researchers at St. Michael's Hospital developed a mathematical model to evaluate the impact of PrEP on the number of new HIV infections among gay men in Toronto, the number of HIV-related deaths averted and the cost impact on the health-care system. Their findings were published online recently in the Journal of the International AIDS Society.

Previous studies have found that a daily dose of Truvada, a Health-Canada approved preventative oral medication, could reduce HIV acquisition in men who have sex with men by 44 per cent, or as much as 99 per cent with high adherence.

The model developed at St. Michael's suggests that over 20 years, PrEP use in 25, 50, 75, and 100 per cent of the highest risk gay men would prevent 1,166, 2,154, 2,816 and 3,012 new HIV infections, and 70, 117, 137, and 140 HIV-associated deaths. The estimated cost of implementing PrEP would increase as more high-risk men used it, from $80 million with 25 per cent PrEP coverage to $270 million with 100 per cent PrEP coverage.

Putting gay men on preventative therapy could have the added benefit of bringing them into contact with the health care system, meaning they are more likely to be tested regularly for HIV and to have other health issues diagnosed and-or attended to, said one of the paper's authors, Dr. Darrell Tan, an infectious disease specialist who led a PrEP clinical trial at St. Michael's.

Dr. Tan and his colleagues found that although testing alone prevented fewer infections than use of PrEP, there was a reduction in cost to the health care system ($11,359 per infection prevented) by screening these high-risk patients regularly.

Dr. Tan said one thing that makes this study different is that it focuses exclusively on Toronto. Most models of PrEP's clinical- and-or cost-effectiveness are based on national-level sexual behaviours and data. But Dr. Tan said a national perspective can ignore local or regional differences, whereas strong local data can be more persuasive in shaping local policy and programs.

Of the estimated 57,400 gay men living in Toronto, nearly 20 per cent have HIV. Despite the availability of anti-retroviral therapy drugs and sustained investments in behavioural prevention programs, rates of newly diagnosed HIV infections and HIV-attributable deaths have not markedly declined in this demographic group in the last 10 years.

Finally, Dr. Tan said the growing evidence of PrEP's clinical and cost effectiveness comes at a time when some provinces are considering whether to cover the expensive drug on publicly funded insurance plans. The drug now costs between $12,000 and $15,000 a year, meaning it is affordable only to people in clinical trials or with private insurance.

"This study makes a strong argument for public reimbursement of this drug," said Dr. Tan. "It's more evidence the drug is both clinically and cost effective when targeted at men at highest risk. A large benefit comes from engaging non-diagnosed HIV-infected men into care."
-end-
This study received funding from the Canadian Institutes of Health Research.

About St. Michael's Hospital


St. Michael's Hospital provides compassionate care to all who enter its doors. The hospital also provides outstanding medical education to future health care professionals in more than 23 academic disciplines. Critical care and trauma, heart disease, neurosurgery, diabetes, cancer care, and care of the homeless are among the Hospital's recognized areas of expertise. Through the Keenan Research Centre and the Li Ka Shing International Healthcare Education Center, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael's Hospital are recognized and make an impact around the world. Founded in 1892, the hospital is fully affiliated with the University of Toronto.

For more information, please contact:

Leslie Shepherd
Manager, Media Strategy
Phone: 416-864-6094
shepherdl@smh.ca

http://www.stmichaelshospital.com

Follow us on Twitter: http://www.twitter.com/stmikeshospital

St. Michael's Hospital

Related Hiv Articles:

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.
The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.
Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.
NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
First ever living donor HIV-to-HIV kidney transplant
For the first time, a person living with HIV has donated a kidney to a transplant recipient also living with HIV.
More Hiv News and Hiv Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...